Currently, eliminationof autoreactive B cells is accomplished by administration of the monoclonalanti-CD19/20 antibody, Rituximab (Rituxan, MabThera), which is extensively usedin the therapy of lymphomas and autoimmune diseases [7-12]. The gene discussed is CD19; the disease is autoimmune disease.